✦ LIBER ✦

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

✍ Scribed by Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.- H.; Quah, C.; Lee, L. F.; Cortes, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of older patients with HER2-po

✍ Miles, David; Baselga, José; Amadori, Dino; Sunpaweravong, Patrapim; Semiglazov, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 282 KB

Incidence and risk of central nervous sy

✍ Olson, E. M.; Abdel-Rasoul, M.; Maly, J.; Wu, C. S.; Lin, N. U.; Shapiro, C. L. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 243 KB

Randomized phase III trial of trastuzuma

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Phase II Trial of Weekly Docetaxel, Vino

✍ Jeffrey R. Infante; Denise A. Yardley; Howard A. Burris III; F. Anthony Greco; C 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 120 KB

Multicenter study of weekly trastuzumab,

✍ J. Salvador; M. Ruiz-Borrego; J. Bayo-Calero; M. Lomas-Garrido; A. Moreno-Vega; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

1BA Subcutaneous Administration of Trast

✍ C. Jackisch; D. Stroyakovskiy; S. Muehlbauer; D. Heinzmann; M.V. Kopp; J.S. Ahn; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB